CancerDrs

Prostate Cancer clinical trials in South Carolina

37 actively recruiting prostate cancer trials at 12 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in South Carolina:
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Self Regional Healthcare — Greenwood, South Carolina
  • Gibbs Cancer Center-Pelham — Greer, South Carolina
  • Spartanburg Medical Center — Spartanburg, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Levine Cancer Institute-Rock Hill — Rock Hill, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in South Carolina:
  • Saint Francis Hospital — Greenville, South Carolina
  • Saint Francis Cancer Center — Greenville, South Carolina
  • Self Regional Healthcare — Greenwood, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …

Sponsor: Pfizer
NCT ID: NCT07028853
Sites in South Carolina:
  • Grand Strand Medical Center — Myrtle Beach, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
  • Parkway Surgery Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in South Carolina:
  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in South Carolina:
  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in South Carolina:
  • Hollings Cancer Center — Charleston, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Sponsor: Pfizer
NCT ID: NCT06629779
Sites in South Carolina:
  • AUC Urologists, LLC — Myrtle Beach, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
  • Grand Strand Medical Center — Myrtle Beach, South Carolina
  • Parkway Surgery Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in South Carolina:
  • Research Site — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

PSMA PET Combined With MRI for the Detection of PCa

This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in South Carolina:
  • Atlantic Urology Specialists — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in South Carolina:
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Gibbs Cancer Center-Pelham — Greer, South Carolina
  • Spartanburg Medical Center — Spartanburg, South Carolina
  • SMC Center for Hematology Oncology Union — Union, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in South Carolina:
  • Site US10018 — Charleston, South Carolina
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
  • Site US10003 — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Sponsor: Dendreon
NCT ID: NCT06134232
Sites in South Carolina:
  • Lowcountry Urology Institute — Charleston, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in South Carolina:
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…

Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in South Carolina:
  • Research Site — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in South Carolina:
  • START Carolinas — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…

Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in South Carolina:
  • Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants …

Sponsor: Hoffmann-La Roche
NCT ID: NCT07287150
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer

This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized…

Sponsor: Medical University of South Carolina
NCT ID: NCT05586360
Sites in South Carolina:
  • Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →

Showing 25 of 37 trials with sites in South Carolina. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10